$AMWL

Zamansky Dmitry sold $79K of AMWL

Zamansky Dmitry (Chief Product & Tech. Officer) sold 8,460 shares of American Well Corp (AMWL) at $9.33 on 2026-07-01.

Original reporting
SEC EDGAR · Zamansky Dmitry
Published Jul 1, 2026, 9:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 9:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AMWL
Neutral
high confidence
Mentioned
$AMWL
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMWLNeutralLow
01

Why it matters

This provides a fresh datapoint on insider activity but does not disclose any new operational, financial, or regulatory development for AMWL.

02

Market read

Useful for monitoring insider behavior, but the disclosed sale size and lack of accompanying corporate news suggest limited trading impact.

03

What to watch

No 10b5-1 plan is stated; traders may over-interpret intent. Also, insider sales often cluster around personal tax/liquidity events rather than fundamentals.

Relevance 3/10Novelty 5/10Timing: filed 2026-07-01 (after-hours) for an insider sale executed the same day

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for American Well Corp (AMWL).

Company-level read

Ticker impact

$AMWLNeutralHigh confidence
Context

SEC Form 4 shows AMWL officer Zamansky sold 8,460 shares on 2026-07-01 at $9.33, totaling about $78.9K.

Expected impact

Minimal near-term impact; any effect is likely short-lived and outweighed by broader fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with modest dollar value and no 10b5-1 plan disclosed; it does not include new company guidance, contracts, or regulatory actions.

Market effects

No clear sector read-through; this is company-specific insider dealing without operational updates.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification or liquidity needs and may not reflect negative expectations, especially given the small size relative to typical institutional flows.

Key entities

  • AMWL

    American Well Corp; subject of the Form 4 insider sale disclosure.

  • Zamansky Dmitry

    Chief Product & Tech Officer; reported open-market sale of 8,460 shares.

Related articles

$QTTBMedAI 8/10

Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus

Biotech gainers highlighted Q32 Bio (QTTB), up 90.7% to $21.38 after positive Phase 2 SIGNAL-AA results for bempikibart in alopecia areata, and it launched a $200M underwritten stock offering. Agenus (AGEN) rose 82.7% to $6.12 on a planned ~$85M private placement for BOT+BAL Phase 3 ROBBIN1. Other movers: ACTU, GALT, AMWL, SI.